Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial

The Lancet Oncology

Volumn 16, Issue 4, 2015, Pages 447-456

  Krug, Lee M ^a   Kindler, Hedy L ^b   Calvert, Hilary ^c   Manegold, Christian ^d   Tsao, Anne S ^e   Fennell, Dean ^f   Öhman, Ronny ^g   Plummer, Ruth ^h   Eberhardt, Wilfried E E ⁱ   Fukuoka, Kazuya ^j   Gaafar, Rabab M ^k   Lafitte, Jean Jacques ^l   Hillerdal, Gunnar ^m   Chu, Quincy ⁿ   Buikhuisen, Wieneke A ^o   Lubiniecki, Gregory M ^p   Sun, Xing ^p,q   Smith, Margaret ^p   Baas, Paul ^o,r  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k CAIRO UNIVERSITY   (Egypt)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

^o NETHERLANDS CANCER INSTITUTE   (Netherlands)

^p MERCK RESEARCH LABORATORIES   (United States)

^q SANOFI   (France)

^r ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; PLACEBO; VORINOSTAT;

ADULT; ADVERSE DRUG REACTION; AGED; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; HYDROXAMIC ACIDS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLACEBOS;

EID: 84933526775     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70056-2     Document Type: Article

References (29)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
2. Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014, 84:271-274.
3. Marks PA, Richon VM, Miller T, Kelly WK Histone deacetylase inhibitors. Adv Cancer Res 2004, 91:137-168.
4. Paik PK, Krug LM Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010, 5:275-279.
5. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001, 25:562-568.
6. Neuzil J, Swettenham E, Gellert N Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun 2004, 314:186-191.
7. Symanowski J, Vogelzang N, Zawel L, Atadja P, Pass H, Sharma S A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 2009, 4:149-160.
8. Bolden JE, Peart MJ, Johnstone RW Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
9. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999, 81:54-61.
10. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468-475.
11. Dubey S, Jänne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010, 5:1655-1661.
12. West AC, Smyth MJ, Johnstone RW The anticancer effects of HDAC inhibitors require the immune system. OncoImmunology 2014, 3:e27414.
13. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
14. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7:257-261.
15. Byrne MJ, Nowak AK Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
16. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
17. Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drus 2008, 26:483-488.
18. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008, 19:964-969.
19. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
20. Gehan EA The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961, 13:346-353.
21. Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009, 4:97-101.
22. Vandermeers F, Hubert P, Delvenne P, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009, 15:2818-2828.
23. Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2011, 37:129-135. the European Lung Cancer Working Party (ELCWP).
24. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 2010, 126:743-755.
25. Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007, 13:3605-3610.
26. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:56-62.
27. Chen L, Vogelzang NJ, Blumenstein G, et al. Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer. Proc Am Soc Clin Oncol 2007, 25(suppl):18088. (abstr).
28. Krug LM, Arduino JM, Sun X, et al. Forced vital capacity (FVC) as a reproducible measure of pulmonary function in chemotherapy-pretreated patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2011, 29(suppl):7028. (abstr).
29. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011, 43:668-672.